Express News | Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target
BenzingaApr 29 08:05 ET
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Serum 4-HNE levels are increased in bulbar vs. limb onset ALS patients and correlate with shortened survival in patients with bulbar onset ALS;
Business WireApr 26 08:15 ET
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer
BusinesswireApr 22 08:15 ET
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief
BusinesswireApr 18 08:15 ET
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April 26, 2024. The title of the poster is 4-hydroxynonenal (4-HNE) as a Biomarker in ALS.
BusinesswireApr 8 08:15 ET
We're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn Rate
Yahoo FinanceMar 27 08:37 ET
Coya Therapeutics Inc (COYA) Reports Fiscal 2023 Financial Results and Corporate Updates
Yahoo FinanceMar 21 05:31 ET
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Coya Therapeutics, Inc. (COYA) and Iovance Biotherapeutics (IOVA)
TipRanksMar 20 06:01 ET
Coya Therapeutics Is Maintained at Buy by Chardan Capital
Coya Therapeutics Is Maintained at Buy by Chardan Capital
Dow JonesMar 20 05:41 ET
Express News | Chardan Capital Maintains Buy on Coya Therapeutics, Raises Price Target to $14
Moomoo 24/7Mar 20 05:31 ET
Coya Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/20/2024 31.09% Chardan Capital $11 → $14 Maintains Buy 08/09/2023 162.17% EF Hutton → $28 Reiterates Bu
BenzingaMar 20 05:29 ET
Strengthened Financials and Promising Pipeline Position Coya Therapeutics for Success
TipRanksMar 20 02:25 ET
Coya Therapeutics GAAP EPS of -$0.79
Seeking AlphaMar 19 10:21 ET
Coya Therapeutics Financial Update and Performance Review
TipRanksMar 19 08:32 ET
Coya Therapeutics FY23 EPS $(0.79) Vs $(4.73) YoY; Collaboration Revenue Of 6M
Financial ResultsAs of December 31, 2023, Coya had cash and cash equivalents of $32.6 million and received an additional $7.5 million in January from Dr. Reddy's as an upfront payment as part of the C
BenzingaMar 19 08:19 ET
Press Release: Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results HOUSTON--(BUSINESS WIRE)--March 19, 2024-- Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a
Dow JonesMar 19 08:15 ET
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
Stockhouse Mar 19 08:15 ET
Buy Recommendation for Coya Therapeutics on Promising Neurodegenerative Disease Treatment Approach
TipRanksMar 10 17:26 ET
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
Regulatory T cell (Treg) immunomodulatory function significantly compromised and inflammatory cytokines and chemokines significantly increased in FTD patients COYA 302, Coya's lead investigational product, is believed
BusinesswireMar 6 08:15 ET
Coya Therapeutics(COYA.US) Director Buys US$3,620 in Common Stocks
$Coya Therapeutics(COYA.US)$ Director Lee Ann purchased 1,000 shares of Common Stocks on Aug 22, 2023 at an average price of $3.62 for a total value of $3,620.Source: Announcement What is statement of
moomoo NewsMar 5 20:42 ET
No Data
No Data